# Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

> **NCT01348490** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 66 (actual)

## Conditions studied

- MPN (Myeloproliferative Neoplasms)

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT01348490
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-15
- **Primary completion:** 2018-12-19
- **Final completion:** 2018-12-19
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2020-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01348490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01348490, "Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01348490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*